Credevo

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Credevo, Health/Medical/ Pharmaceuticals, Singapore.

A global Clinical Trial Organization (CTO) providing comprehensive clinical trial services for pharmaceuticals, biologics, medical devices and healthcare products Credevo provides strategic support for healthcare products including;

- Drugs

- Biologics

- Health Supplements (Nutraceuticals)

- IVD and medical devices

- Cosmetics

In areas of

- Regulatory

- Clinical Development

- Business Development Support

- Licensing (out-/in-)

- Feasibility

30/07/2026

The comparator arm was built from published treatment guidelines.

The problem was that investigators at the target sites in Southeast Asia were following a different protocol in clinical practice, a variation from the standard guideline that had become routine at those institutions. If the comparator arm had gone into the study as written, the sponsor would have been measuring the investigational product against a comparator that patients in the study weren't consistently receiving.

This was found during investigator engagement, four weeks before the protocol was scheduled to lock.

The fix was straightforward once the discrepancy was visible: revise the comparator arm definition before lock. A protocol amendment after enrolment would have required regulatory resubmission, ethics review, and a delay that adds months to the timeline, with the compounding cost of a multi-site study running against a protocol that needed correction.

Early site engagement finds this kind of problem because it asks the right questions at the right time. Not a feasibility questionnaire sent to site coordinators, but a substantive conversation with investigators about what the study would actually look like at their site, the patients, the practice patterns, the comparators in use.

The specifics of what investigator engagement catches, and what it doesn't, are covered in detail here: https://credevo.com/articles/2025/05/15/why-early-site-engagement-matters-insights-into-soc-comparator-arms-and-site-interest/

If your protocol is approaching lock and hasn't been reviewed against actual investigator practice in the target markets, we're here: https://credevo.com/contact

29/07/2026

Sri Lanka is an underused market for APAC clinical trials.

Strong patient access in oncology, infectious disease, and general medicine. Investigator interest in international studies. A National Medicines Regulatory Authority (NMRA) process that, once understood, has clear submission requirements. Operating costs that compare well to the larger APAC markets.

One factor that affects whether sponsors use this market is access to FSP staffing with genuine in-country knowledge, people who know how the NMRA process works, which sites have the institutional infrastructure to run a trial, and how to operate within the local clinical environment.

Under the FSP model, Credevo provides Clinical Research Associates (CRAs) and clinical trial managers based in Sri Lanka, working in your systems, under your SOPs, with your oversight. They know the sites, the investigators, and how things actually move in this market.

Credevo's FSP network covers Sri Lanka alongside India, Thailand, Malaysia, and Singapore.

We've written about what the FSP model looks like in practice for India-based programs, the structural logic applies across APAC markets including Sri Lanka. https://credevo.com/articles/2025/02/25/smarter-clinical-trial-management-in-india-why-the-fsp-functional-service-provider-fsp-model-makes-sense/

If you're evaluating Sri Lanka for an upcoming program, we're available to talk through what's practical: https://credevo.com/contact

28/07/2026

When a Contract Research Organisation (CRO) submits a proposal, the quality section describes its own processes. What it may not address is how those processes will interact with yours.

For sponsors with an established Quality Management System (QMS), this gap is structural. The CRO has Standard Operating Procedures (SOPs) for monitoring, data management, adverse event reporting, and regulatory filing. The sponsor has SOPs for the same functions. Somewhere between those two systems there is a reconciliation that needs to happen, and if it isn't mapped before ex*****on starts, it gets resolved ad hoc, function by function, when it becomes a problem.

The right time to address this is before first patient in, not after.

Credevo maps SOP and process integration with the sponsor's quality requirements before ex*****on begins. The outcome is an agreed, documented framework: which functions run under sponsor SOPs, which under CRO SOPs, and where both systems interface. No ambiguity about what applies when.

For sponsors from manufacturing backgrounds, regulated industries, or any context where the quality framework needs to hold exactly as written through the study, this is the foundation, not an implementation detail.

If your quality system has requirements that need to be reflected in how your next study is structured, we're happy to work through what that looks like: https://credevo.com/contact

27/07/2026

A published regulatory timeline in APAC covers the formal review process: the submission window, the review period, the decision timeline. The query response cycles, current regulatory backlog, how a particular agency is handling this study type right now, and what gets flagged in practice versus what the guidance says gets flagged, these are the variables that determine whether the published timeline holds.

The gap between the documented framework and operational reality is where studies stall. A sponsor planning a startup timeline from published guidance is building on a floor that was correct when the guidance was written and may have shifted since.

Credevo's regulatory teams are active in the markets they support rather than reading guidance documents from a distance, but running current submissions and seeing what the actual timeline looks like for comparable study types right now. That operational view is what gets built into the plan.

We've written about what navigating clinical operations across APAC looks like in practice, including where regulatory timelines diverge from what the documentation suggests. https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If you're building a regulatory timeline for an APAC study and want a current-state read on the market you're planning in, we're available: https://credevo.com/contact

24/07/2026

You sent an update request to three different people last week. You're still waiting.

Multi-country studies fragment accountability when study management is distributed across markets. When something needs a fast decision, the gaps become gaps in accountability, not just coordination.

Credevo runs multi-country studies with centralised management at HQ. One dedicated senior project manager for the full study duration. Questions, updates, and escalations go to one person. Standard response within 36 to 48 hours.

What effective clinical trial project management looks like in practice: https://credevo.com/articles/2024/08/15/project-management-in-clinical-trials-a-comprehensive-guide/

If you're running a multi-country study and want to talk through the accountability structure, we're here: https://credevo.com/contact

23/07/2026

A study that runs on the wrong EDC configuration doesn't fail at lock. It fails in the first month.

EDC, eTMF, eConsent, and IRT each have to be set up, configured, and validated before the study opens. Systems adapted from a previous study without verification, or configured during ex*****on, create compounding problems across the full study duration.

Credevo provides clinical trial systems as standalone services: licensing, setup, configuration, validation, and ongoing support. For sponsors who need specific system infrastructure without a full CRO engagement.

A guide to the clinical trial systems that underpin modern trial management: https://credevo.com/articles/2025/06/25/a-guide-to-essential-clinical-trial-tools-systems-for-smarter-faster-studies/

If you need systems set up and validated before your study opens, we're here: https://credevo.com/contact

22/07/2026

Malaysia's NPRA approval timeline for a clinical trial application looks reasonable. Sponsors who have run studies there know the preparation required to actually hit it.

NPRA issues queries. The question is whether the initial submission gives the authority everything needed to avoid additional rounds, and whether queries are responded to quickly when they come. Both are preparation problems, not regulatory problems.

Sponsors building their first Malaysia timeline from the published framework plan around the nominal approval period. They don't plan for a query cycle. When one occurs, the startup extends, site readiness windows reset, and in competitive enrollment environments the delay affects which sites are still available.

The difference between a smooth NPRA process and a drawn-out one is almost always in the submission package: documents prepared to Malaysian requirements, query responses that match what NPRA is actually asking, and a coordinated ethics and regulatory timeline running in parallel.

Credevo runs full-service clinical trials in Malaysia with on-ground teams who know the current regulatory process.

What APAC clinical operations actually involves in practice: https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If Malaysia is in your program and you'd like a realistic read on the regulatory process, we're here: https://credevo.com/contact

21/07/2026

Most of what gets written about APAC trials is written for companies that have already done it before.

For a biotech planning its first study in the region, the main questions are which markets fit the program, how the regulatory processes actually work, and what makes site selection reliable.

The regulatory processes differ significantly by country. Site selection is a relationship process, not a database query. Total study cost looks different from the per-patient headline figure.

Credevo is locally embedded across 13 APAC markets, built for sponsors without large internal clinical teams.

What goes into choosing the right APAC market for your trial: https://credevo.com/articles/2023/08/25/choosing-asia-pacific-for-your-clinical-trials-strategic-insights/

If you're working out whether and where to run your first APAC study, we're here: https://credevo.com/contact

20/07/2026

The protocol looked reasonable. First patient consent was months ago. Now recruitment isn't moving.

High screening failure rates. Comparator arms that don't reflect current clinical practice at target sites. Eligibility criteria that exclude too many patients. These problems are predictable. They become visible when you engage investigators before the protocol is locked, not after.

Problems found at design stage are cheap to fix. The same problems found after site activation and first patient consent are expensive.

What early site engagement surfaces before protocol lock: https://credevo.com/articles/2025/05/15/why-early-site-engagement-matters-insights-into-soc-comparator-arms-and-site-interest/

If you're approaching protocol lock and want an investigator review, we're here: https://credevo.com/contact

17/07/2026

Most content about APAC clinical trials was written for sponsors who have already run trials there.

Country guides, regulatory timelines, patient population breakdowns. Useful for sponsors calibrating an existing APAC program. Less useful for the one entering for the first time, who needs to know how published timelines compare to actual experience, what the local sponsor representative function means in practice, why site selection can't be a database exercise, and which budget assumptions from home market programs don't transfer.

We've covered what choosing APAC for clinical trials actually involves in practice: https://credevo.com/articles/2023/08/25/choosing-asia-pacific-for-your-clinical-trials-strategic-insights/

If you're entering APAC for the first time and want a practical briefing on what you're planning for, we're here: https://credevo.com/contact

Address

Singapore

Website

https://credevo.com/

Alerts

Be the first to know and let us send you an email when Credevo posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

The Prenatal Consultants
101 Irrawaddy Road, #15-05/06 Royal Square Medical Centre
Ojas Yoga and Wellness
359a Joo Chiat Road